Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Novel technique may cut cost of bronchitis vaccine production
Infectious bronchitis remains a major problem in the global poultry industry. Because
Researchers grow IBV cell cultures in the laboratory

New research led by The Pirbright Institute could result in low-cost infectious bronchitis vaccine (IBV) production.

In a study published in the Journal of Virology, researchers describe how they genetically modified an IBV strain so that it could be grown in cell cultures in the laboratory, rather than inside hen eggs.

It is hoped the technique could lower the cost of vaccine production and make the process more efficient.

“To find the genetic code that made the lab strain able to replicate in cell cultures, we scanned the gene that produces the spike protein—the protein which enables the virus to attach to and enter cells—and found a genetic sequence which was unique to that virus,” explained Dr Bickerton, leader of the Coronaviruses group at Pirbright.  

“We were able to cut this sequence out of the lab strain and replace it in the vaccine strain to see if this allowed the vaccine strain to replicate in cell cultures too.”

Interestingly, the team discovered the sequence which allows lab growth of IBV strains results in the change of only three amino acids in the spike protein.

Dr Bickerton adds: “We can now apply this modification to other IBV vaccine strains, which will help improve the speed and efficiency of IBV studies and can eventually be applied to vaccine production”.

Despite there being an array of vaccines in existence, infectious bronchitis remains a major problem in the global poultry industry. Because the majority of IBV strains do not grow in cell cultures, IBV vaccines are grown in hen's eggs -  a process that is cumbersome and expensive.

Researchers estimate that a 10 per reduction in IBV incidence could save the global poultry industry £654 million. Boosting the efficiency and speed of IBV vaccine production is, therefore, crucial to reducing economic losses and welfare problems in chickens.

Become a member or log in to add this story to your CPD history

Webinar to explore AMR in vet dentistry

News Story 1
 The WSAVA has invited veterinary professionals to a webinar on responsible antibiotic usage in dentistry.

On 19 November 2025, at 1am, Dr J Scott Weese and Dr Brooke Niemiec will share the latest advice for antimicrobial use. They will present research on oral bacterology, and explain how attendees can choose appropriate antibiotics.

The session will cover pre-, intra- and post-operative guidelines, with recommendations for various pathologies.

The webinar is designed to support veterinary professionals to make informed decisions and tackle antimicrobial resistance.

Attendees can register here

Click here for more...
News Shorts
Dechra launches checklist for veterinary sustainability

Global animal health specialist Dechra has announced the world's first Veterinary Green Theatre Checklist (VGTC) to help make surgery more sustainable.

Endorsed by leading veterinary organisations, including the BEVA, BVNA and RCVS Knowledge, the checklist is designed to reduce the environmental footprint of veterinary care, while supporting better animal health outcomes.

The checklist was launched at the World Congress of Veterinary Anaesthesia and Analgesia in Paris and will be followed by an internal training and awareness campaign. For more information, visit dechra.com